The success of tissue regenerative therapies is contingent on functional and multicellular vasculature within the redeveloping tissue. Although endothelial cells (ECs), which compose the vasculature's inner lining, are intrinsically able to form nascent networks, these structures regress without the recruitment of pericytes, supporting cells that surround microvessel endothelium. Reconstruction of typical in vivo microvascular architecture traditionally has been done using distinct cell sources of ECs and pericytes within naturally occurring matrices; however, the limited sources of clinically relevant human cells and the inherent chemical and physical properties of natural materials hamper the translational potential of these approaches. Here we derived a bicellular vascular population from human pluripotent stem cells (hPSCs) that undergoes morphogenesis and assembly in a synthetic matrix. We found that hPSCs can be induced to codifferentiate into early vascular cells (EVCs) in a clinically relevant strategy amenable to multiple hPSC lines. These EVCs can mature into ECs and pericytes, and can self-organize to form microvascular networks in an engineered matrix. These engineered human vascular networks survive implantation, integrate with the host vasculature, and establish blood flow. This integrated approach, in which a derived bicellular population is exploited for its intrinsic self-assembly capability to create microvasculature in a deliverable matrix, has vast ramifications for vascular construction and regenerative medicine.
The success of tissue regenerative therapies is contingent on functional and multicellular vasculature within the redeveloping tissue. Although endothelial cells (ECs), which compose the vasculature's inner lining, are intrinsically able to form nascent networks, these structures regress without the recruitment of pericytes, supporting cells that surround microvessel endothelium. Reconstruction of typical in vivo microvascular architecture traditionally has been done using distinct cell sources of ECs and pericytes within naturally occurring matrices; however, the limited sources of clinically relevant human cells and the inherent chemical and physical properties of natural materials hamper the translational potential of these approaches. Here we derived a bicellular vascular population from human pluripotent stem cells (hPSCs) that undergoes morphogenesis and assembly in a synthetic matrix. We found that hPSCs can be induced to codifferentiate into early vascular cells (EVCs) in a clinically relevant strategy amenable to multiple hPSC lines. These EVCs can mature into ECs and pericytes, and can self-organize to form microvascular networks in an engineered matrix. These engineered human vascular networks survive implantation, integrate with the host vasculature, and establish blood flow. This integrated approach, in which a derived bicellular population is exploited for its intrinsic self-assembly capability to create microvasculature in a deliverable matrix, has vast ramifications for vascular construction and regenerative medicine.
codifferentiation | hydrogels P erhaps the greatest roadblock to the success of tissue regenerative therapies is the establishment of a functional microvascular network to support tissue survival and growth (1) . Microvascular construction or regeneration depends on endothelial morphogenesis into a 3D tubular network, followed by stabilization of the assembling structures by recruited pericytes (2, 3) . To create such a construct for therapeutic applications, patient-derived ECs and pericytes must be incorporated into a synthetic matrix, which confers an advantage in controlling and modulating vascular morphogenesis and also represents a clinically relevant construct in which to deliver the engineered microvascular networks to in vivo environments (4) .
Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced PSCs (hiPSCs), offer the opportunity to derive EVCs from the same source, which offers patient specificity. Various cell markers have been proposed to identify vascular precursors (of ECs and pericytes) from differentiating hPSCs including CD34 (5, 6) , VEGF receptor-2 (VEGFR2)/kinase domain receptor (KDR) (7) , and apelin receptor (8) . Purification of such progenitors is required from an uncontrolled differentiated cell population [i.e., via embryoid body (EB) formation or coculture on mouse feeder layer] through marker enrichment or selection through genetic manipulation. Importantly, none of these derived cells have been demonstrated to self-assemble into functional microvasculature containing both ECs and pericytes.
Current approaches for the differentiation of hPSCs toward the vascular lineage typically use a purified, single derivative-either a progenitor or a mature cell type-with the goal of fully characterizing the fidelity of differentiation from a PSC. From this body of work, it has become apparent that various cell markers and biochemical cues can be used to guide differentiation and derive functional ECs (5, (9) (10) (11) (12) , vascular smooth muscle cells (5, 11, 13) and pericytes (14) . Building on these previous studies, in the present study we hypothesized that hPSCs can be induced to differentiate into early derivatives of the vascular lineage (i.e., EVCs) that compose the microvascular architecture without a specific differentiation-inducible feeder layer, EB formation, or genetic manipulation (Fig. 1A, i) ; and that such EVCs can mature into ECs and pericytes and can self-assemble to form vascular networks in an engineered matrix (Fig. 1A , ii).
We present a unique conceptual approach in which the cells of the microvasculature are derived in a bipotent population, which is able to recreate the tissue. Our protocol uses a monolayer culture and avoids an EB intermediate and sorting, thereby enabling reproducibility and clinical applicability. We harness intrinsic tissue-level differentiation and self-assembly capabilities toward the translational realization of hPSCs. This paradigm could prove useful for the construction of other multicellular tissues for regeneration.
Results and Discussion
Derivation of EVCs from hPSCs. Toward clinically relevant outcomes, and because microvascular architecture is a bicellular entity, we first sought to develop a robust and controlled method to differentiate hPSCs into a bicellular vasculogenic population with maturation capacity to both ECs and pericytes. CD105 and CD146 are common to both cell types (14) (15) (16) (17) , whereas vascular endothelial cadherin (VEcad) has been shown to specify a lineage commitment of ECs (10) . Although no single marker designates pericytes, pericytes can be distinguished by the expression of platelet-derived growth factor β (PDGFRβ) in conjunction with CD146 (18) .
Acknowledging that cocultures of pericytes and ECs typically result in pericyte-mediated EC growth inhibition (14, 19) , we focused on inducing VEcad + cells early in the differentiation process to ensure EC maturation. Building on previous work (10, 20, 21), we developed a stepwise differentiation procedure to induce vascular lineage specification. hPSCs (SI Appendix, Table  S1 ) were first allowed to undergo differentiation in a monolayer (SI Appendix, Fig. S1 ). The subsequent addition of TGF-β inhibitor SB431542 (10), supplemented with either high (50 ng/mL) or low (1 ng/mL) concentrations of VEGF-A yielded up-regulation of VEcad expression ranging from 20% to 60% VEcad + cells, depending on hPSC line ( Fig. 1B and SI Appendix, Fig. S2 ).
Under our differentiation strategy, hESC line H9 exhibited the greatest potential to yield the largest percentage of VEcad + cells compared with hiPSC lines BC1 and MR31. The expression levels of CD31 were not changed under the various conditions, whereas VEGFR2/KDR expression was higher in media supplemented with a low VEGF concentration (SI Appendix, Fig. S3 ). Expression of tumor rejection antigen (TRA)-1-60 and TRA-1-81, markers of pluripotency, was <1% when using high VEGF concentrations, indicating that the vast majority of cells had been differentiated (Fig. 1C and SI Appendix, Fig. S3 ). Thus, in all experiments, EVCs were differentiated in medium supplemented with SB431542 and with high VEGF concentrations.
EVCs derived from multiple hPSC lines using high VEGF concentrations and SB431542 were highly purified (>95%) for CD105 and CD146, surface antigens common to both ECs and pericytes ( Fig. 1D and SI Appendix, Fig. S4 A-C), expanding on a previously reported approach that sorted out a CD105
+ population from spontaneously differentiating EBs with the focus on pericytes (14) . By eliminating a sorting step and guiding hPSCs toward a bipotent population, our approach builds on this previous study and provides a unique strategy to yield a CD105 +
CD146
+ population that composes the bicellular microvascular architecture in a controlled, efficient, and robust manner.
Without our specific inductive protocol (i.e., removal of VEGF and SB431542 supplementation), hiPSC-BC1 cells differentiated for 12 d were still fairly well enriched in CD105 (95%) and CD146 (93%); however, hESC-H9 cells differentiated for 12 d without these inductive conditions expressed ∼90% CD105 + cells and only 54% CD146 + cells (SI Appendix, Fig. S4D ). Importantly, both H9 and BC1 differentiated cell populations expressed very low levels of VEcad. These results, along with the aforementioned finding that high VEGF supplementation ensures <1% TRA-1-60 + cells in the various hPSC types ( Fig. 1C and SI Appendix, Fig. S3 ), further support our choice of inductive media conditions.
Using our approach, we derived CD105 + CD146 + EVCs at an approximate ratio of 1:1 of input hPSC to EVC (Fig. 1E) . The number of input hPSCs was calculated as the number seeded at day 0, not the number of cells present after 1 d of differentiation, as reported previously (10 eNOS was undetected in all tested BC1 samples. Sorted VEcad − cells exhibited greater expression of pericyte markers PDGFRβ and NG2 compared with EVCs and sorted VEcad + cells. Our analysis also revealed differences in the differentiation potential between hESC-H9 and hiPSC-BC1 lines using the adherent, stepwise differentiation protocol, suggesting that hESC-H9-differentiating cells may mature more rapidly toward these lineages, owing to the fact that 12-d differentiated H9-EVCs started to express eNOS at the mRNA level and yielded a greater percentage of VEcad + (Fig. 1B) and CD31 + cells at the protein level (SI Appendix, Fig. S3 ) compared with the tested hiPSC lines.
EVCs were negative for hematopoietic marker CD45 (Fig.  1H) , and demonstrated negligible expression of the smooth muscle cell marker smooth muscle myosin heavy chain (SMMHC), as well as the peripheral neuron marker peripherin (Fig. 1I) . Comparable marker expression profiles were obtained from EVCs derived using serum-free conditions in our adherent differentiation scheme (SI Appendix, Fig. S6 ). Based on these analyses, we considered this derived population to be vascular lineagespecific and composed of early ECs and early pericytes. It should be noted that these are not mature ECs and pericytes, given that 12 d of differentiation was not sufficient to mature hPSCs toward matured phenotypes, in agreement with numerous previous studies (5, 14, 23 ).
Maturation of EVCs: ECs. We took two approaches to examine the endothelial potential of hPSC-EVCs, (i) subculturing EVCs and (ii) sorting and expanding VEcad + cells, both under the same culture conditions (i.e., 50 ng/mL VEGF and SB431542). Subculturing yielded ECs that were enriched in VEcad and CD31 (SI Appendix, Fig. S7 A and B) ; however, this approach and enrichment without cell sorting varied among three different hPSC lines, and a hiPSC line with vector integration demonstrated the best results (SI Appendix, Fig. S7C ). Sorted VEcad 
CD31
+ CD146 + ECs (Fig. 2A) . The cells exhibited typical membrane expression of VEcad and CD31, lectin binding, cytoplasmic expression of eNOS and von Willebrand factor (vWF), uptake of acetylated low-density lipoprotein (acLDL), up-regulation of intercellular adhesion molecule 1 (ICAM1) in response to TNF-α, and network formation on Matrigel ( Fig. 2B and SI Appendix, Fig. S7 D and E). We did not detect lectin, eNOS, vWF, or acLDL uptake via immunofluorescence in our unsorted EVC populations, demonstrating that no subpopulation of EVCs expresses these EC characteristics and that additional culture is needed to mature early ECs from EVCs. These findings were consistent among the different hPSC lines examined.
Maturation of EVCs: Pericytes. We next probed the pericyte potential of the EVCs. EVCs, which do not express NG2 (SI Appendix, Fig. S8A ), were cultured under pericyte-inducing conditions (19) . After 6 d of culture, cells were enriched in pericyte markers CD73, NG2, PDGFRβ, and CD44 (24) and depleted in EC markers VEcad and CD31 ( Fig. 2C and SI Appendix, Fig. S8A ). Interestingly, most cells retained CD146 + expression, but some lost CD105 expression (Fig. 2C) . The spindle-shaped pericyte derivatives expressed PDGFRβ and NG2 proteoglycan and exhibited filamentous calponin expression (Fig. 2D ), as would be expected for pericytes derived from fetal and adult sources. Sorted VEcad + cells were not able to attach and grow under pericyte-maturing conditions. An important function of pericytes is their ability to behave as mesenchymal precursors (14, 18) . Indeed, the pericyte derivatives in our culture could be differentiated to adipocytes and osteoblasts (SI Appendix, Fig. S8 
CD146
+ PDGFRβ + subtypes contain the cellular makeup necessary for constructing a microvasculature.
Self-Organization of Bicellular Vascular Networks in Hydrogels.
To examine whether EVCs could be leveraged to self-organize into a bicellular microvascular bed, we tested network formation in collagen (2, 25) and in completely synthetic hyaluronic acid (HA)-based hydrogel (3) (Fig. 3A and SI Appendix, Fig. S10 ). We speculated that derived EVCs would be able to form vascular networks in a 3D matrix. Indeed, in both hydrogel systems, EVCs were found to form lavish networks (Fig. 3A) ; sorted VEcad + or VEcad − cells individually were unable to form such networks when encapsulated within collagen gels ( formed primarily vacuoles and started to form nascent structures within the collagen gel, with some instances of sprouting ( Fig. 3B) .
We attribute the lack of robust network formation from derived ECs in collagen gels to the lack of pericytes in culture, and speculate that the addition of support cells help form the networks seen with EVC encapsulation. VEcad − cells exhibited cell spreading and a characteristic stellate morphology, but no network formation (Fig. 3B ).
Vascular Morphogenesis of EVCs Within HA Hydrogels. We next examined the progress of EVC network formation within the HA hydrogel, a xeno-free synthetic construct engineered to recapitulate tubulogenesis-inducing signals (3). In vitro assessment of cellular behavior revealed the formation of multicellular networks via a sequential process typical of vascular morphogenesis. After 1 d of culture, we observed vacuole formation in many, but not all, of the cells. Some of these vacuoles had coalesced into a larger structure, resembling lumen ( Fig. 3C and SI Appendix, Fig. S11A ).
To elucidate the phenotype of either cell type after 1 d, we also encapsulated VEcad + and VEcad − subpopulations independently. After 1 d, we clearly observed vacuoles in the encapsulated sorted VEcad + subpopulation after 1 d; however, encapsulated sorted VEcad − cells primarily spread, with no vacuole formation (SI Appendix, Fig. S11 B and C) .
After 2 d of EVC encapsulation, we observed the progression of tubulogenesis, including extensive sprouting and an occasional open lumen (Fig. 3D and SI Appendix, Fig. S12A ). By day 3, vascular networks had grown, with comprehensive multicellular networks clearly visible within HA hydrogels. Complex vascular networks with patent lumen structures were readily detected throughout the hydrogels, suggesting an engineered vascular network ( Fig. 3E and SI Appendix, Fig. S12B ). Interestingly, on day 3, we detected NG2 + pericytes incorporated in the luminal structures and encircling the emerging tubular structures (Fig. 3F and SI Appendix, Fig. S13 ).
Integration of hPSC-Bicellular Microvascular Constructs. In vivo integration of vascular networks is crucial to the success of derived EVCs in regenerative medicine applications. We first tested whether EVCs can survive implantation, assemble into microvascular networks, integrate with the host vasculature, and establish blood flow. A Matrigel plug assay (5) revealed EVCs incorporated with perfused host microvasculature and generated human-only microvascular structures (SI Appendix, Fig. S14 ).
Next, to harness the self-organizing capability of EVCs in HA hydrogels, we implanted the engineered microvascular networks s.c. and assessed their survival and integration after 2 wk. We found that EVCs (derived from a BC1 or GFP-hiPSC cell line) were incorporated into or wrapped around the mouse microvasculature (Fig. 4 A and B and SI Appendix, Fig. S15 ), and that the hydrogels were largely degraded by 2 wk. HA gels without encapsulated cells exhibited slower remodeling and degradation in vivo compared to gels with cells, as we reported previously (3). Perfused microvasculature (as indicated by tail-injected, mousespecific fluorescein-conjugated GS-IB4 lectin) containing human ECs (with cross-sectional areas ranging from 100 to 25,000 μm 2 ) were abundant throughout the explant (∼15 vessels per mm 2 ), demonstrating that the transplanted human vascular networks had anastomosed with the host circulatory systems (Fig. 4 C-E) .
Moreover, NG2
+ human pericytes were found to migrate toward and encircle the perfused vasculature ( Fig. 4F and SI Appendix, Fig. S16 ).
Although our bicellular constructs present several fundamental advancements to the future of cell-based therapies, additional studies are needed to fine-tune the ratio of early ECs to pericytes within EVC populations, owing to the wide variability of this ratio in different tissues and organs (26). Further investigation is also needed for clinical translation, including understanding of cell-cell interactions and appreciation of the longevity and durability of the human vascular networks. Future studies should focus on determining the in vivo longevity of engineered human networks to reveal not only the long-term integration of the human vasculature in the tissue, but also whether teratoma formation is of concern, a vital consideration of pluripotent stem cell therapies. The balance between commitment and plasticity of the EVCs specifically within the vascular lineage allows for vascular fate and network maturation. This controlled system is reproducible, generates physiologically relevant vascular networks in implantable matrices, and thus provides the next fundamental step toward patient-specific engineered tissue with clinically translatable potential.
Experimental Procedures
Detailed descriptions of the materials and methods used in this study are provided in SI Appendix, Materials and Methods.
hPSC Culture. The hESC lines H9 and H13 (passages 15-40; WiCell Research Institute) and hiPSC lines MR31 (27), MMW2 (28), BC1 (29, 30), and a GFP transgenic hiPSC line (clone 26 hCBiPS aMHCneoPGKhygro + pCAGGS2 passage 47+10, kindly provided by Dr. Ulrich Martin, Hannover Medical School, Hannover, Germany) (31) were cultured as described previously (13, 32) . Cell lines were routinely examined for pluripotent markers using immunofluorescence staining and flow cytometry analysis for TRA-1-60, TRA-1-81, stage-specific embryonic antigen-4 (SSEA4), and Oct4. Details of the various hPSCs are provided in SI Appendix, Table S1 .
Differentiation Protocol. hPSCs were collected through digestion with EDTA (Promega), separated into an individual cell suspension using a 40-μm mesh strainer (BD Biosciences), and plated onto collagen IV (Trevigen)-coated plates at a concentration of 5 × 10 4 cells/cm 2 . Cells were cultured for 6 d in a differentiation medium composed of alpha-MEM (Invitrogen), 10% FBS (HyClone), and 0.1 mM β-mercaptoethanol (β-ME), with the medium changed daily. On day 6, differentiated cells were collected through digestion with TrypLE (Invitrogen), separated with a 40-μm mesh strainer, and seeded at a concentration of 1.25 × 10 4 cells/cm 2 on collagen type IV-coated plates in endothelial cell growth media (ECGM) (PromoCell) supplemented with 2% FBS, 50 ng/mL VEGF with or without 10 μM SB431542 (Tocris), or 1 ng/mL VEGF plus 10 μM SB431542, for 6 d. The medium was changed every other day.
To elucidate whether serum-free conditions could be used to derive EVCs, we followed the aforementioned protocol, except differentiating the cells in alpha-MEM media supplemented with 20% knockout serum replacement, 0.1 mM β-ME, 1× nonessential amino acids (Gibco), and 1× L-glutamine (Invitrogen) for 6 d, followed by 6 d in ECGM base media (Promocell) supplemented with 50 ng/mL VEGF, 10 μM SB431542, 10% knockout serum replacement, β-ME, essential amino acids, and glutamine. These conditions were used only when specified in the text for serum-free differentiation. IV-coated dishes for an additional 6 d in ECGM supplemented with 50 ng/mL VEGF and 10 μM SB431542. The medium was changed every other day.
Pericyte Maturation. We followed a published protocol for pericyte maturation (19) . On day 12, derived EVCs were collected through digestion with TrypLE and replated on tissue culture-treated six-well plates in medium composed of DMEM and 10% FBS. After 2-3 h, unattached cells were removed, and the medium was replaced. Cells were cultured for 6 d, with the medium changed every other day.
HA Gels. Acrylated HA hydrogels were prepared as reported previously (3, 33, 34). Derived EVCs or sorted subpopulations were encapsulated in HA hydrogels at a density of 4 × 10 6 cells/mL and cultured for up to 3 d in endothelial growth media 2 (EGM2; Lonza). Visualization and image acquisition were performed using an inverted light microscope (Olympus) and a confocal microscope (Zeiss LSM 510 Meta) along the culture. FM-464 vacuole staining (Invitrogen) was performed following the manufacturer's protocol (3). To test parallel differentiation, EVCs were also cultured in adherent culture in EGM2 for 3 d, with daily medium changes.
Implantation of Cells. Except for GFP-hiPSC-derived cells, all other PSCs (hiPSC-MR31, hESC-H9, hiPSC-BC1)-derived cells were labeled with PKH-26 (red) according to the manufacturer's protocol and as described previously (13) . PKH-26-labeled cells were resuspended with Matrigel and 50 ng/mL bFGF or engineered vascular networks in HA gels for 3 d, then implanted s.c. into nude 6-to 8-wk-old female mice in quadruplicate. To visualize angiogenesis in the implants before sample removal after 2 wk, we injected Alexa Fluor 488 (or in some cases, Alexa Fluor 546 or 647)-conjugated isolectin GS-IB4 from Griffonia simplicifolia (Invitrogen) through the tail veins of the mice (35). After 20 min, mice were euthanized by CO 2 asphyxiation, after which the explants were harvested and fixed in 3.7% formaldehyde (Sigma-Aldrich) and proceeded for visualization and sectioning. The Johns Hopkins University's Institutional Animal Care and Use Committee approved all animal protocols.
Graphs and Statistics. All analyses were performed in triplicate samples for n = 3 at least. Quantitative RT-PCR was also performed on triplicate samples (n = 3) with triplicate readings. One-way ANOVA with the Bonferroni post hoc test were performed to determine significance using GraphPad Prism 4.02. Hannover Medical School, Germany) (4) were cultured as previously described (5-6). Cell lines were routinely examined for pluripotent markers using immunofluorescence staining and flow cytometry analysis for TRA-1-60, TRA-1-81, SSEA4, and Oct4. See Table S1 for details on the various hPSCs.
Differentiation protocol. Human PSCs were collected through digestion with ethylenediaminetetraacetic acid (EDTA; Promega), separated into an individual cell suspension using a 40-µm mesh strainer (BD Biosciences), and plated onto collagen IV (Trevigen) coated plates at a concentration of 5x10 4 cells/cm 2 . Cells were cultured for 6 days in a differentiation medium composed of alpha-MEM (Invitrogen), 10% FBS (Hyclone) and 0.1 mM β-mercaptoethanol (β-ME), with the media changed daily. On day 6, differentiated cells were collected through digestion with TrypLE (Invitrogen), separated with a 40-µm mesh strainer, and seeded at a concentration of 1.25x10 4 cells/cm 2 on collagen-type-IV-coated plates in endothelial cell growth media (ECGM) (PromoCell) supplemented with 2% FBS, 50ng/ml VEGF with or without 10µM SB431542 (Tocris), or 1ng/ml VEGF + 10µM SB431542, as described in the text for 6 days. Media was changed every other day. To elucidate whether serum-free conditions could be used to derive EVCs, we followed the aforementioned protocol except differentiating the cells in alpha-MEM media supplemented with 20% knockout serum replacement, 0.1 mM β-ME, 1x non-essential amino acids (Gibco), and 1X L-glutamine (Invitrogen) for 6 days, followed by 6 days in ECGM base media (Promocell) supplemented with 50ng/ml VEGF, 10µM SB431542, 10% knockout serum replacement, β-ME, essential amino acids, and glutamine. These conditions were used only where specified in the text.
Flow cytometry. Flow cytometry was performed as previously described (7). Briefly, cells were incubated with FITC-or PE-conjugated antigen specific antibodies for markers outlined in the text (Table S2 ). All analyses were done using corresponding isotype controls. Forward-side scatter plots were used to exclude dead cells. User guide instructions were followed to complete the flow cytometry analysis via Cyflogic v1.2.
Real-time quantitative RT-PCR. Two-step reverse transcription polymerase chain reaction (RT-PCR) was performed on differentiated and undifferentiated (day 0) hPSCs as previously described in accordance with Applied Biosystems manufacturer instructions (7). For each primer set (VEcad, SMMHC, Tuj1, peripherin, and ICAM), we used the comparative computerized tomography method (Applied Biosystems) to calculate the amplification differences between different samples. The values for experiments were averaged and graphed with standard deviations.
Immunofluorescence. Cells were prepared for immunofluorescence as previously described (7). Briefly, fixed cells were blocked in 1% BSA, treated with 0.1% Triton-X (Sigma), and incubated with the antigen specific antibodies for the markers outlined in the text (Table S2) , followed by an appropriate secondary, and DAPI (Roche Diagnostics). The immunolabeled cells were examined using a fluorescent microscope (Olympus BX60).
EC maturation. On day 12, derived EVCs were either sub-cultured in differentiation medium or sorted for VEcad + cells. For this, EVCs were collected through digestion with Magnetic Activated Cell Sorting (MACS) buffer (0.5M EDTA and 1% BSA in PBS), incubated with 10ul anti-human, PE-conjugated VEcad (BD) in MACS buffer for 45 minutes on ice, washed, incubated with 20 ul anti-PE microbeads (Miltenyi Biotec) in 80ul MACS buffer for 15 minutes at 4°C, and washed twice. Cells were re-suspended in 500µl MACS buffer and separated using a MS MACS separation column (Miltenyi Biotec). VEcad enrichment or depletion was confirmed by flow cytometry. Sorted cells were cultured on collagen-type-IV-coated dishes for an additional 6 days in ECGM supplemented with 50ng/ml VEGF and 10µM SB431542. Media was changed every other day.
Dil-labeled Ac-LDL uptake. Derived ECs were incubated with 10 μg/ml Dil-labeled Ac-LDL (Invitrogen) for 4 hours at 37°C, rinsed three times with PBS, fixed with 4% paraformaldehyde for 30 minutes, and visualized using a fluorescence microscope (Olympus).
Tumor Necrosis Factor alpha (TNF-α) activation. A previously established protocol for the activation of ECs was used (8) . Briefly, cultured cells were stimulated for 24 hours with 10 ng/ml tumor necrosis factor-alpha (TNF-α; R&D) or blank as a control and analyzed for ICAM (Applied Biosystems).
Matrigel cord formation. Cells were labeled with PKH-26 (red) according to the manufacturer's protocol. Briefly, cells were mixed with diluents C and PKH-26 for 5 minutes. The reaction was stopped by adding Hyclone FBS and the cells were washed three times. Cells were observed for their ability to form cord structures on Matrigel (BD Bioscience) as previously described (5). Briefly, Matrigel was cast into μ-Slide Angiogenesis wells (iBidi, Munich, Germany). After polymerization, 20,000 PKH-stained cells were seeded per well. Visualization and image acquisition were performed using fluorescence microscopy (Olympus BX60) after 24 hours. Pericyte maturation. We followed a published protocol for pericyte maturation (9) . Briefly, On day 12, derived EVCs were collected through digestion with TrypLE and re-plated on tissue culture treated 6 well plates in media comprised of DMEM and 10% FBS. After 2-3 hours, unattached cells were removed and media was replaced. Cells were cultured for 6 days, changing the media every second day.
Mesenchymal differentiation (adipogenic and osteogenic).
For adipogenic differentiation (10), we cultured derived pericytes at 10,000cells/cm 2 in media comprised of DMEM, 10% FBS, 1% Penicillin/Streptomycin, 200µM Indomethacin, 500 µM 3-Isobutyl-1-methyl xanthine (IBMX), and 5 µg/ml Insulin (all from Sigma) for 4 weeks. To assess adipogenic potential, cells were fixed with 3.7% formaldehyde, then dehydrated with 60% isopropanol for 5 minutes. Cells were incubated with Oil Red O (Sigma) at 1.8 mg/ml in 60/40 isopropanol/DI H 2 O, for 10 minutes and imaged using an inverted light microscope (Olympus).
For osteogenic differentiation (11), we cultured derived pericytes at 5,000cells/cm 2 in media comprised of low glucose DMEM, 10% FBS, 1% Penicillin/Streptomycin, 10mM β-glycerophosphate, 100nM dexamethasone, and 50 µM ascorbic acid (all from Sigma) for 2 weeks. Media were prepared fresh weekly. To assess osteogenic potential, samples were fixed with 3.7% formaldehyde, and washed with DI H 2 O. Samples were incubated with Alizarin Red S (40mM in DI H 2 O, pH ~4.2; Sigma) for 10-20 minutes.
Collagen gel assay. Stock solution was used to prepare collagen gels at a density of 2.5 mg/ml, as previously described in the literature. Gel formation was achieved by simultaneously decreasing the solution's pH and increasing the temperature to 37°C. To prepare 1 ml of 2.5 mg/ml collagen gel, we added 2 million derived cells (EVCs, VEcad+ cells, or VEcad-cells) resuspended in 200 ul M199 [1X] to a mixture of 39 µl M199 [10x] + 400.6 µl M199 [1X] . To this, we added 350 µl Collagen Type I. After the addition of approximately 10 µl of 1M NaOH, the solution was thoroughly mixed and transferred to wells of a 96 well plate. ECGM supplemented with 50ng/ml VEGF was added to the gels after 30 minutes at 37°C in a CO 2 incubator. Visualization and image acquisition were performed using an inverted light microscope (Olympus).
Synthesis of HA gels. Acrylated HA (AHA) hydrogels were prepared as previously reported (12) (13) . Briefly, AHA was synthesized using a two-step protocol: (1) the tetrabutylammonium salt of HA (HA-TBA) was formed by reacting sodium hyaluronate (64 kDa; Lifecore Biomedical, Chaska, MN) with the highly acidic ion exchange resin Dowex-100 and neutralizing with 0.2 M TBA-OH; (2) acrylic acid (2.5 Eq) was coupled to HA-TBA (1 Eq, repeat unit) in the presence of dimethylaminopyridine (DMAP; 0.075 Eq) and di-tert-butyl dicarbonate (1.5 Eq) in DMSO, followed by dialysis and lyophilization.
1 H NMR was used to confirm the final percent modification of the AHA. 
EVC, sorted VE-Cad
+ and sorted VE-Cad -subpopulation encapsulation and culture. AHA polymer (3 wt%) was dissolved in a sodium phosphate buffered saline (NaPBS buffer: 0.1 M sodium phosphate, 0.3 M total osmolarity, pH 8.0. The cell adhesive peptides (RGDS; GenScript) were dissolved in NaPBS buffer and added to the AHA solution at final peptide concentration of 3.7 mM and allowed to react for one hour with gentle shaking. Recombinant human VEGF 165 (Pierce), bFGF (Invitrogen), Ang-1 (R&D), tumor necrosis factor-alpha (TNF-α; R&D) and stromal cell-derived factor-1 (SDF-1; R&D) were added at 50 ng/ml into the AHA-RGDS mixture. Derived EVCs or sorted subpoluations were encapsulated in HA hydrogels at a density of 4 X 10 6 cells/ml. Following the resuspension of cells, the MMP solution was added at 4.83 mM (corresponding to the 25 percent of available acrylate groups within the 3 wt% AHA). Immediately after adding the MMP crosslinker, 40 µl of this mixture was pipetted into sterile molds (5 mm diameter, 2 mm height) and allowed to react for 15 minutes at room temperature inside the laminar flow hood. The formed constructs were cultured for up to three days in endothelial growth media 2 (EGM2; Lonza). Visualization and image acquisition were performed using an inverted light microscope (Olympus) and a confocal microscope (LSM 510 Meta; Carl Zeiss) at various times during culture. We performed FM-464 vacuole staining (Invitrogen) following the manufacturer's protocol. To test parallel differentiation, day 12 EVCs were also cultured in adherent culture in EGM 2 (Lonza) for 3 days with media changed daily.
Subcutaneous implantation of cells. Except for GFP-hiPSC derived cells, all other PSCderived cells were labeled with PKH-26 (red) according to the manufacturer's instructions. Labeled cells, which were re-suspended with growth factor-reduced Matrigel (BD) and 50ng/ml bFGF or engineered vascular networks in HA gels for 3 days were implanted subcutaneously into nude 6-8 week old female mice in quadruplicate. To visualize angiogenesis in the implants prior to sample removal after 2 weeks, we injected Alexa Fluor(R) 488 (or, in some instances, AlexaFluor(R) 647 or 546) conjugated isolectin GS-IB4 from Griffonia simplicifolia (Invitrogen) through the tail veins of the mice (14) . After 20 minutes, mice were euthanized by CO 2 asphyxiation and the explants were harvested and fixed in 3.7 percent formaldehyde (Sigma) and proceeded for visualization and sectioning. The Johns Hopkins University Institutional Animal Care and Use Committee approved all animal protocols.
Histology. The fixed explants were dehydrated in graded ethanol (70%-100%), embedded in paraffin, serially sectioned using a microtome (5 μm), and stained with immunohistochemistry for anti-human CD31 (Dako) and anti-human NG2 (Santa Cruz) (15) (16) . Mouse tissue was used as controls. Blood vessels containing human CD31 cells were counted and measured for area using ImageJ (NIH). We sampled a minimum of 6 images for each construct.
Graphs and Statistics.
All analyses were performed in triplicate samples for n=3 at least. Realtime RT-PCR were also performed on triplicate samples (n=3) with triplicate readings. One Way ANOVA with Bonferroni post-hoc test were performed to determine significance (GraphPad Prism 4.02). Fig. S1 . Differentiating hPSCs. hiPSC-BC1 were differentiated in monolayer for 6 days and analyzed using flow cytometry analysis (n=3) for markers of interest including CD146, CD105, VEcad, and PDGFRβ. Isotype controls for flow cytometry are in gray. Results shown are for hiPSC-BC1 cell line and typical of the independent experiments. Fig. S2 . The effect of VEGF and TGFβ inhibitor on VEcad expression. hPSCs were differentiated in monolayer for 6 days followed by an additional 6 days in medium supplemented with and without SB431542 in low and high VEGF concentrations and analyzed using real-time PCR for VEcad expression (n=3). VEcad expression was upregulated with the addition of TGFβ inhibitor independently of VEGF concentrations in all hPSC lines tested. Significance levels were set at *p<0.05, **p<0.01, and ***p<0.001. Data are reported SEM. Fig. S3 . The effect of VEGF and TGFβ inhibitor on CD31, VEGFR2, and Tra-1-60 expression. hPSCs were differentiated in monolayer for 6 days followed by an additional 6 days in medium supplemented with and without SB431542 in low and high VEGF concentrations and analyzed using flow cytometry (n=3) for CD31, VEGFR2, and Tra-1-60 expression in (A) hESC-H9 and (B) hiPSC-MR31 lines. CD31 expression did not change in the different treatments, while VEGFR2 expression was upregulated in media supplemented with low VEGF concentration. Tra-1-60 expression was downregulated to <1% in conditions supplemented with high VEGF. Data are reported SEM. (B) immunofluorescence staining on cross sections of explants. Scale bar is 20 μm, and (C) immunohistochemistry for human NG2 (in brown; an example is indicated by arrow). Scale bar is 10 μm.
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